DNTH Latest Press Releases

-- October 13, 2026 --

Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharma Globe Newswire 8:45 AM

-- October 1, 2026 --

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 5:00 PM

-- September 29, 2026 --

Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting Globe Newswire 8:00 AM

-- September 2, 2026 --

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 5:00 PM

-- September 1, 2026 --

Dianthus Therapeutics to Participate in Three Investor Conferences During September Globe Newswire 8:00 AM

-- August 10, 2026 --

Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors Globe Newswire 4:07 PM

-- August 4, 2026 --

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results Globe Newswire 4:01 PM

Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases Globe Newswire 7:00 AM

-- August 3, 2026 --

Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) Globe Newswire 6:00 PM

-- July 2, 2026 --

Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4) Globe Newswire 4:01 PM

-- June 29, 2026 --

Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis Globe Newswire 7:00 AM

-- June 2, 2026 --

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- May 26, 2026 --

Dianthus Therapeutics to Participate in Two Investor Conferences Globe Newswire 4:01 PM

Market Data Delayed 15 Minutes